

# Novel Technology on Neo-Two Cancers (Bladder and Prostate Cancers) Screening

Chong Li



## ABSTRACT

Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. There were 1.3 million new cases in 2018. The top 20 countries with the highest rates of prostate cancer in 2018 include UK and France. The prostate cancer has become the second most common cancer of urinary system in China. Consequently, there's no doubt that bladder cancer and prostate cancer have been two leading killers in urinary system, here, we define them as "neo two cancers" with "neo" prefixed to make it distinguished from women's two most common cancers, breast cancer and cervical cancer. Early detection is the major challenge. We established a highly sensitive method to detect cancer antigen in urine using LS-MS-MS screening (US patent and published in Mol cancer, cancer+, Clin Cancer Res, Eur Urol, and Cancer Res). The goal of the study is to develop affordable, accurate and non-invasive technology available to the World through collaborations.

## BIOGRAPHY

Chong Li, Ph.D of Peking University, currently Professor of the Institute of Biophysics, CAS and Director of the Medical Immunodiagnostic Research Center the Institute of Biophysics, CAS, was born in 1972. He has a long career in basic and translational medicine research of tumor immunology and antibody drugs. The total IF of his articles published is more than 300. Also, he has published 8 academic monographs and been authorized for more twenty patents both in China and the United States. Meanwhile, he has hosted dozens of national and local foundation projects covering the Ministry of Science and Technology of China, National Natural Science Foundation of China, Chinese Academy of Sciences, etc. He has organized to carry out several scientific and technological plans in the advanced clinical area such as China Neo-two Cancers (bladder and prostate cancers) Screening and China Bladder Cancer Precision Medicine Plan, etc. Also, he has been granted several times for Science & Technology Award, Innovation & Venue Award, etc., including The First Prize of Beijing Science and Technology Award, The First Prize of Yunnan Science and Technology Progress Award.



28<sup>th</sup> International Conference on Cancer Research and Pharmacology, July 01, 2020, Paris, France

Zhongke Jianlan Medical Institute, China

Citation: Chong Li, Novel Technology on Neo-Two Cancers (Bladder and Prostate Cancers) Screening, Cancer Research 2020, 28<sup>th</sup> International Conference on Cancer Research and Pharmacology, July 1, 2020, Paris, France, pp.3